Palvella (PVLA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$21.9M

Net income growth (year over year)

−130.92%

Net margin

—

Return on equity

−46.63%

EPS (trailing twelve months)

−$4.85

Book value per share

$15.06

P/E (trailing twelve months)

—

Price to book

8.88

Debt to assets

14.45%

Payout ratio

—

Dividend yield

—

Company profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

• How do I buy stock in Palvella (PVLA)?

  PVLA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.